Benitec Biopharma reported $51.2 million in fiscal-year expenses and a $45.5 million net loss attributable to shareholders, or $0.98 per basic and diluted share. Its $180.0 million cash balance and BB-301 milestones matter to investors as the company anticipates a pivotal trial in mid-2027.

Key Highlights

  • All Cohort 1 patients completed the full post-treatment follow-up, while Cohort 2 became fully enrolled with all patients safely treated.
  • Interim BB-301 results were accepted for a late-breaking presentation at the ESGCT Congress beginning October 27, 2026.
  • Cash and cash equivalents totaled $180.0 million at June 30, 2026.
  • BB-301 showed clinically meaningful improvements in swallowing symptoms and assessments, with a key trial anticipated in mid-2027.

Benitec Biopharma Inc. (NASDAQ: BNTC) had $180.0 million in cash and cash equivalents at June 30, 2026, while its BB-301 program progressed through clinical follow-up, enrollment and regulatory planning.

BB-301 Trial Advances Toward Key Planning

The company observed clinically meaningful improvements in patient-reported swallowing symptoms and X-ray-based swallowing assessments, including throat closing, throat emptying, throat muscle relaxation and functional swallowing ability. Benitec anticipates initiating the key trial in mid-2027.

Clinical Spending and Fiscal-Year Losses

Research and development costs reached $23.4 million, compared with $18.3 million in the prior year. The increase primarily reflected $6.3 million in share-based compensation and $2.2 million in payroll, partly offset by $3.8 million less contract Manufacturing activity. General and administrative expenses were $27.8 million versus $23.4 million, driven mainly by $2.7 million in share-based compensation and $0.8 million in payroll.